| Title |
Baseline glucose homeostasis predicts the new onset of diabetes during statin therapy: A retrospective study in real life
|
|---|---|
| Published in |
Hormones international journal of endocrinology and metabolism, January 2018
|
| DOI | 10.14310/horm.2002.1760 |
| Pubmed ID | |
| Authors |
Maria Chantal Ponziani, Ioannis Karamouzis, Chiara Mele, Luisa Chasseur, Marco Zavattaro, Marina Caputo, Maria Teresa Samà, Arianna Busti, Loredana Pagano, Luigi Castello, Paolo Marzullo, Gianluca Aimaretti, Flavia Prodam |
| Abstract |
We evaluated the risk of altered glucose levels and new-onset diabetes (NOD) associated with statins according to glucose levels at baseline in a population treated for dyslipidemia on primary prevention for >5 years. The retrospective study included 308 subjects (265 on statins and 43 controls on diet) with a follow-up of 5-15 years. The cohort was classified according to glucose tolerance at both baseline and follow-up. The cumulative incidence of NOD was 13.6% (9.3% in controls and 13.5% in treated patients). NOD was diagnosed after 3.4±1.8 years. In the group with normal glucose levels at baseline, a family history of diabetes (OR: 3.4, 95% CI 1.3-8.9), BMI >30 kg/m2 (OR: 8.5, 95% CI 2.0-35.8), treatment with thiazide (OR: 21.9, 95% CI 1.2-384.2) and no alcohol consumption (OR: 0.3, 95% CI 0.1-0.8) reduced the risk of developing altered glucose levels or NOD. No effects of statins were seen. In the group with altered glucose levels at baseline, hypertension (OR: 5.0, 95% CI 1.0-25.3) and hypertriglyceridemia (OR: 3.5, 95% CI 1.0-11.8) increased the risk of remaining with altered glucose levels or developing NOD. Treatment with statins (OR: 7.5, 95% CI 1.5-37.4), in particular atorvastatin, was associated with an increased risk. In the whole population, statin therapy (OR: 4.0, 95% CI 1.1-14.1, p<0.020), and in particular simvastatin and atorvastatin, was associated with increased risk of altered glucose levels or NOD. Patients who developed or maintained altered glucose levels or NOD had a poor metabolic phenotype at baseline. Statins were associated with an increased risk of NOD or altered glucose levels, mainly in subjects with altered glucose levels before the beginning of therapy. Poor metabolic phenotype and unhealthy behaviors or family history of diabetes contributed to that risk. |
X Demographics
The data shown below were collected from the profiles of 17 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 29% |
| Australia | 2 | 12% |
| Mexico | 1 | 6% |
| South Africa | 1 | 6% |
| Unknown | 8 | 47% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 53% |
| Practitioners (doctors, other healthcare professionals) | 5 | 29% |
| Scientists | 2 | 12% |
| Science communicators (journalists, bloggers, editors) | 1 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 31 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 7 | 23% |
| Student > Master | 5 | 16% |
| Researcher | 3 | 10% |
| Other | 1 | 3% |
| Librarian | 1 | 3% |
| Other | 4 | 13% |
| Unknown | 10 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 29% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Biochemistry, Genetics and Molecular Biology | 2 | 6% |
| Nursing and Health Professions | 2 | 6% |
| Immunology and Microbiology | 1 | 3% |
| Other | 2 | 6% |
| Unknown | 13 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 March 2022.
All research outputs
#3,239,072
of 25,382,440 outputs
Outputs from Hormones international journal of endocrinology and metabolism
#45
of 459 outputs
Outputs of similar age
#70,676
of 449,219 outputs
Outputs of similar age from Hormones international journal of endocrinology and metabolism
#2
of 13 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 459 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 449,219 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.